Can a common gout pill help fight Obesity-Related health problems?

NCT ID NCT05017571

Completed Disease control Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This completed Phase 2 trial tested whether colchicine, an anti-inflammatory drug, can improve insulin resistance in 152 adults and adolescents with obesity. Participants took either colchicine or a placebo daily for 12 weeks. The study measured changes in insulin resistance and inflammation markers to see if reducing inflammation could improve metabolism.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If successful, this could point toward a new way to improve metabolism and reduce diabetes risk in people with obesity by targeting inflammation.
What could go wrong: This is a small, early-phase trial. The results may not be strong enough to change practice, and colchicine can cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Inflammation inflammatory disease Insulin Resistance Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATION INSULIN RESISTANCE OBESITY

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.